RDTC Logo

Regional Drug & Therapeutics Centre

University Emblem

 Page: Evaluation Reports

Home
About us
Management
Publications
Education
Services
Links
Contact us
Search

RSS Feed

Evaluation Reports
 

These drug reviews aim to give objective information and guidance to commissioners of health services, prescribers and others both on clinical aspects of the subject and on arrangements for prescribing. The reports are prepared by a multidisciplinary team within the RDTC and reviewed by health authority personnel and appropriate external specialists. However, the responsibility for the content and conclusions rests solely with the RDTC.

This information is produced for use by NHS healthcare professionals. See site disclaimer.
 

The following documents are provided in Adobe Acrobat format.

Other publications:

Academic Detailing

Drug Updates

Monthly Horizon Scanning Reports

New Drug Evaluations

Publications by
BNF category

Rapid Appraisals

Safer Medication Use (ADR section)

 

 

Services:

Prescribing support

 Report name

Date

The use of panitumumab in the management of metastatic
colorectal cancer

Jun 09

The use of ibritumomab as consolidation therapy after remission induction in previously untreated follicular lymphoma

May 09

The use of azacitidine for the management of myelodysplastic syndromes

May 09

The use of aprepitant for the prevention of chemotherapy induced nausea and vomiting

Mar 09

Current therapeutic strategies for pulmonary arterial hypertension

Mar 09

The use of lapatinib in the management of metastatic breast cancer

Nov 08

Myocet in the management of metastatic breast cancer

Oct 08

Dasatinib in the management of acute lymphoblastic leukaemia
in adults

Aug 08

Bevacizumab in metastatic breast cancer

Sep 07

Entecavir in chronic hepatitis B

Apr 07

Natalizumab in multiple sclerosis (N)

Mar 07

Aromatase inhibitors in early stage breast cancer (N)

Mar 07

Alemtuzumab in chronic lymphocytic leukaemia

Mar 07

Palonosetron for the prevention of nausea and vomiting associated with cancer chemotherapy

Mar 07

Omalizumab in severe persistent allergic asthma (N)

Jun 06

Rituximab in combination with cvp chemotherapy for the management of follicular non-hodgkin’s lymphoma

Mar 06

Ibritumomab in b-cell follicular non-hodgkin’s lymphoma

Mar 06

Erlotinib in non-small cell lung cancer

Mar 06

Docetaxel or paclitaxel in early stage breast cancer (N)

Mar 06

Bortezomib second-line in multiple myeloma (N)

Mar 06

Pemetrexed in malignant pleural mesothelioma (N)

Mar 06

Pegvisomant in acromegaly

Jan 06

Ibandronic acid in hypercalcaemia of malignancy, bone pain and the prevention of skeletal events associated with skeletal metastases

Aug 05

Teriparatide in osteoporosis (N)

Jul 04

Adefovir dipivoxil in chronic hepatitis B infection (N)

Jun 04

An update on newer agents for the treatment of pulmonary hypertension.

Mar 04

Drotrecogin alfa (activated) in severe sepsis (N)

Dec 02

For a list of documents prior to the date of the earliest publication shown
please see the Evaluation Reports archive page

Back button

Page last updated 04/01/2010

Site Disclaimer 

Privacy Statement 

Feedback 

Site Map 

Copyright 

RSS Feed

Site last updated 20/01/2010

valid-html401-blue